BioScrip Inc. (NASDAQ:BIOS) was up 2.7% on Thursday . The company traded as high as $2.67 and last traded at $2.65, with a volume of 450,016 shares trading hands. The stock had previously closed at $2.58.

Separately, Zacks Investment Research upgraded BioScrip from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a research report on Monday, July 11th.

The company has a 50-day moving average of $2.63 and a 200-day moving average of $2.24. The company’s market cap is $185.71 million.

BioScrip (NASDAQ:BIOS) last posted its quarterly earnings data on Thursday, May 5th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.05. During the same period last year, the business earned ($0.17) EPS. The firm earned $238.50 million during the quarter, compared to analysts’ expectations of $232.38 million. BioScrip’s quarterly revenue was down 2.4% compared to the same quarter last year. Analysts expect that BioScrip Inc. will post ($0.20) EPS for the current year.

In other news, Director David W. Golding bought 12,500 shares of the company’s stock in a transaction that occurred on Friday, June 17th. The stock was bought at an average price of $2.48 per share, with a total value of $31,000.00. Following the acquisition, the director now owns 42,500 shares of the company’s stock, valued at approximately $105,400. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Coliseum Capital Management, L bought 4,200,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 22nd. The stock was purchased at an average cost of $2.00 per share, with a total value of $8,400,000.00. The disclosure for this purchase can be found here.

Other hedge funds and institutional investors have recently modified their holdings of the company. Gamco Investors INC. ET AL increased its position in shares of BioScrip by 1.4% in the fourth quarter. Gamco Investors INC. ET AL now owns 864,850 shares of the company’s stock valued at $1,513,000 after buying an additional 12,250 shares in the last quarter. Diamond Hill Capital Management Inc. increased its position in shares of BioScrip by 2.5% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 3,055,476 shares of the company’s stock valued at $5,347,000 after buying an additional 74,757 shares in the last quarter. Finally, Gabelli Funds LLC increased its position in shares of BioScrip by 22.9% in the fourth quarter. Gabelli Funds LLC now owns 11,430,900 shares of the company’s stock valued at $20,004,000 after buying an additional 2,132,060 shares in the last quarter.

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.